Multiply Labs

The Short Version

Multiply Labs is building robotic biomanufacturing infrastructure to automate the sterile, high-throughput production of individualized drugs and gene-modified cell therapies [NVIDIA Blog]. Founded in 2016 by Fred Parietti and Alice Melocchi, the company has evolved from a concept for 3D-printed personalized pills into a systems provider for industrial-scale cell therapy manufacturing [MIT News, November 2016]. Its core offering combines cloud-controlled modular robotic clusters, which mimic lab workflows through imitation learning, with Digital QC software for process control and compliance [Multiply Labs]. This hardware-plus-software approach targets pharmaceutical and biotech customers, deploying systems as a production capacity service.

The company has secured approximately $41.3 million over multiple rounds from investors including Casdin Capital, Lux Capital, and Y Combinator [The Pharma Letter]. Its business model centers on selling robotic production capacity and systems to customers like AstraZeneca and Legend Biotech. Key indicators to monitor include the scale of deployments from established partnerships, the operational performance of its manufacturing subsidiary in Italy, and the progression from pilot collaborations to broader commercial adoption.

Data Accuracy: GREEN -- Confirmed by multiple independent public sources and company statements.

The Company in Brief

Multiply Labs emerged from the MIT ecosystem in 2016, founded by Fred Parietti and Alice Melocchi [MIT News, November 2016]. The company's initial public wedge was a robotic system for printing customized pharmaceutical capsules [MIT News, November 2016]. Over the subsequent eight years, the company's focus evolved toward the broader challenge of industrial-scale biomanufacturing for cell and gene therapies.

Headquartered in San Francisco, the company operates a robotic pharmaceutical manufacturing facility [LinkedIn]. A key operational milestone was the establishment of Multiply Labs Italia, a manufacturing subsidiary in Turin, Italy, announced in early 2026 [Multiply Labs]. The company's capital formation includes a $25 million Series A round led by Casdin Capital in April 2021, followed by an $11.1 million early-stage round in April 2023 [The Pharma Letter].

Data Accuracy: GREEN -- Founding details confirmed by MIT News and company website. Funding rounds corroborated by The Pharma Letter. Headquarter and subsidiary information sourced from LinkedIn and company press releases.

What They Have Built

Multiply Labs builds robotic systems that replicate the sterile, manual workflows of a cell therapy lab. The company's core offering is a cloud-controlled modular robotic cluster designed to automate the precise, multi-step procedures required to manufacture individualized drugs and gene-modified cell therapies [Multiply Labs]. These systems use 'imitation learning' to mimic human operators, executing protocols for tasks like cell washing, separation, and formulation [PERPLEXITY SONAR PRO BRIEF]. The software layer, Digital QC, provides process planning, real-time sensor monitoring, and automated electronic batch record generation, compliant with FDA regulation 21 CFR Part 11 [Multiply Labs].

Key product surfaces and public deployments include:

• Robotic Biomanufacturing Infrastructure. Multi-arm clusters for industrial-scale production, compatible with market-leading GMP instruments [Multiply Labs].
• Digital QC Software. A cloud-based platform for orchestrating robotic workflows and creating digital records [Multiply Labs].
• Proof-of-Concept Facility. A robotic pharmaceutical manufacturing facility in San Francisco [PERPLEXITY SONAR PRO BRIEF].
• Strategic Integrations. Technology partnerships, including the use of NVIDIA's Isaac robotics platform and Omniverse simulation environment [NVIDIA Blog].

Commercial traction is anchored in named collaborations. The company has announced an expanded partnership with Thermo Fisher Scientific to integrate its robotic technology with Thermo Fisher's instruments [Business Wire, 2024]. It is also collaborating with the Stanford Laboratory for Cell and Gene Medicine [Multiply Labs]. Named pharmaceutical customers include AstraZeneca, Legend Biotech, and Kyverna Therapeutics, with whom Multiply Labs has a pilot to automate production of a CAR T-cell therapy candidate [Multiply Labs, 2025].

Data Accuracy: GREEN -- Product claims and partnerships are confirmed by company press releases and partner announcements.

Market Size and Demand

The demand for automated manufacturing solutions is intensifying as the cell and gene therapy sector moves toward commercial scale. The global cell therapy market is projected to reach $25.2 billion by 2030, growing at a CAGR of 15.5% from 2024 [Precedence Research, 2024]. The gene therapy market is forecast to expand to between $30 billion and $45 billion by 2030 [Grand View Research, 2024], [Allied Market Research, 2024]. The advanced therapy medicinal products (ATMP) manufacturing market is projected to exceed $15 billion by 2030 [Roots Analysis, 2024].

Metric	Value
Cell Therapy Market (2030)	$25,200M
Gene Therapy Market (2030)	$30,000M
ATMP Manufacturing Market (2030)	$15,000M

The primary demand driver is the transition of cell and gene therapies from boutique, hospital-based production to industrialized manufacturing. Manual processes are prone to variability and high labor costs, creating a bottleneck for therapies targeting large patient populations [NVIDIA Blog]. Software like Digital QC addresses the regulatory emphasis on data integrity and process control [Multiply Labs].

Data Accuracy: YELLOW -- Market sizing is based on third-party analyst reports for adjacent sectors; the specific TAM for robotic biomanufacturing infrastructure is not independently verified.

Who Else Is Fighting for This

Multiply Labs operates in a competitive environment defined by established automation incumbents, specialized bioprocess vendors, and robotics-focused challengers. In the broad automation space, traditional industrial robotics leaders like ABB and FANUC offer general-purpose arms, while specialized bioprocess companies like Sartorius and Thermo Fisher Scientific provide integrated instruments. Multiply Labs's collaboration with Thermo Fisher suggests a coopetition model, where Multiply Labs provides the robotic orchestration layer atop established hardware [Business Wire, 2024].

The company's edge lies in its full-stack approach combining hardware, cloud software, and regulatory compliance. The proprietary Digital QC software, described as CFR Part 11 compliant, addresses a critical pain point in GMP environments [Multiply Labs]. This integration, built around imitation learning, creates a technical moat that is difficult for pure-play robotics firms or traditional bioprocess vendors to replicate quickly [PERPLEXITY SONAR PRO BRIEF].

Data Accuracy: YELLOW -- Competitive analysis is inferred from adjacent market players and partnership announcements; no direct competitor names are publicly cited in company materials.

Opportunity

Multiply Labs aims to become the de facto robotic infrastructure layer for commercial-scale cell and gene therapy production. Early traction with top-tier pharmaceutical companies, including AstraZeneca, Legend Biotech, and Kyverna Therapeutics, signals that its robotic systems are being evaluated for commercial-scale production [Multiply Labs]. The collaboration with Stanford's Laboratory for Cell and Gene Medicine provides academic validation [Multiply Labs], while the expanded partnership with Thermo Fisher Scientific suggests a path to integration with industry-standard instruments [Business Wire, 2024].

Data Accuracy: YELLOW -- The core opportunity framing is supported by cited customer and partnership announcements. Market size comparisons are based on common industry estimates.

Sources

1. [The Pharma Letter] Multiply Labs funding rounds | https://www.thepharmaletter.com/article/multiply-labs-secures-11-1-million-in-early-stage-funding
2. [MIT News, November 2016] Print me a pill: Multiply Labs makes robots that print customized pills | https://news.mit.edu/2016/print-me-a-pill-multiply-labs-1102
3. [Multiply Labs] Company website | https://www.www.multiplylabs.com/
4. [NVIDIA Blog] AI’s Next Revolution: Multiply Labs Is Scaling Robotics-Driven Cell Therapy Biomanufacturing Labs | https://blogs.nvidia.com/blog/multiply-labs-isaac-omniverse/
5. [LinkedIn] Multiply Labs company page | https://www.linkedin.com/company/multiply-labs
6. [Multiply Labs, 2025] Multiply Labs partners with Kyverna Therapeutics to pilot robotic automation for KYV-102 | https://www.multiplylabs.com/news/kyverna-partnership-2025
7. [Business Wire, 2024] Multiply Labs Expands Collaboration with Thermo Fisher Scientific to Automate Cell Therapy Manufacturing | https://www.multiplylabs.com/2025/09/30/thermo-dynacellect-announcement/
8. [Precedence Research, 2024] Cell Therapy Market Size Report | https://www.precedenceresearch.com/cell-therapy-market
9. [Grand View Research, 2024] Gene Therapy Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/gene-therapy-market
10. [Allied Market Research, 2024] Gene Therapy Market by Vector Type, Application, and Region | https://www.alliedmarketresearch.com/gene-therapy-market
11. [Roots Analysis, 2024] ATMP Manufacturing Market | https://www.rootsanalysis.com/reports/advanced-therapy-medicinal-products-manufacturing-market.html
12. [Y Combinator] Multiply Labs company profile | https://www.ycombinator.com/companies/multiply-labs